Autopsy report · NCT04460807
Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer
Cause of deathSlow enrollment, also staffing, sites or logistics
“low accrual, COVID 19 emergency and the modification of the standard of care for ovarian cancer treatment”
Life of this trial
- Registered 2 months after it had already started.
- Ran for about 3 years 2 months before it stopped.
- 23 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Ente Ospedaliero Ospedali Galliera
- Sponsor type
- University, hospital or other
- Conditions
- Ovarian Cancer
- Interventions
- Exemestane; Placebo oral tablet
- Participants
- 23
- Sites
- 47
- Countries
- Italy
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.